• Contact us: 01476 247 007
    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    The World Tuberculosis Day – 24 March
    21st March 2019
    Breast Implants Safety Concerns – the Importance of Post-Marketing Surveillance
    4th April 2019

    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019

    4th April 2019

    EU referral procedures for safety reasons:

    • Just started – review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine. The review to examine existing screening methods and their value in identifying patients at increased risk of severe side effects.
      • Patients with low DPD can experience severe side effects due to a build-up of fluorouracil.

    On-going procedures:

    • Methotrexate – JYLAMVO (CAP), NORDIMET (CAP); NAP – EMEA/H/A-31/1463
      • Review of the benefit-risk balance following notification by Spain of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

    Full meeting highlights can be viewed from this link. (Links to a new website)

    New signals detected from other sources

    • Levomethadone (NAP), methadone (NAP) -Signal of opioid toxicity in infants exposed to levomethadone and/or methadone via breast milk
    • Natalizumab – TYSABRI (CAP) – Signal of psoriasis
    • Ondansetron (NAP) – Signal of birth defects following in-utero exposure during the first trimester of pregnancy arising from recent publications
    • Pirfenidone – ESBRIET (CAP) – Signal of hyponatraemia
    • Pirfenidone – ESBRIET (CAP) – Signal of herpes viral infections
    • Sodium-glucose co-transporter 2 (SGLT2) inhibitors: canagliflozin – INVOKANA (CAP); canagliflozin, metformin – VOKANAMET (CAP); dapagliflozin – EDISTRIDE (CAP); dapagliflozin – FORXIGA (CAP); dapagliflozin, Pharmacovigilance Risk Assessment Committee (PRAC) EMA/PRAC/170203/2019 Page 14/60 metformin – EBYMECT (CAP); dapagliflozin, metformin – XIGDUO (CAP); empagliflozin – JARDIANCE (CAP); empagliflozin, metformin – SYNJARDY (CAP); ertugliflozin – STEGLATRO (CAP); ertugliflozin, metformin – SEGLUROMET (CAP) – New information on the known association between sodium-glucose co-transporter 2 (SGLT2) inhibitors and diabetic ketoacidosis (DKA) in surgical patients
    • Tocilizumab – ROACTEMRA (CAP) – Signal of drug reaction with eosinophilia and systemic symptoms (DRESS)
    • Tofacitinib – XELJANZ (CAP) – Signal of increased risk of pulmonary embolism and overall mortality arising from a post-authorisation safety study in patients with cardiovascular risk factors treated for rheumatoid arthritis with tofacitinib 10 mg twice daily

    Signals follow-up and prioritisation

    • Apixaban – ELIQUIS (CAP) – EMEA/H/C/002148/SDA/032.1 -Signal of pancreatitis
    • Belimumab – BENLYSTA (CAP) – EMEA/H/C/002015/SDA/029.1 – Signal of lupus nephritis
    • Nivolumab – OPDIVO (CAP) – EMEA/H/C/003985/SDA/035 – Signal of hypoparathyroidism
    • Paracetamol (NAP) – Signal of paracetamol use in pregnancy and child neurodevelopment and effects on the urogenital apparatus
    • Paracetamol (NAP) – Signal of paracetamol use during pregnancy and premature ductus arteriosus closure in offspring
    • Tocilizumab – ROACTEMRA (CAP) – EMEA/H/C/000955/SDA/053 – Signal of psoriasis
    Share

    Related posts

    MHRA post-transition period information from Pure Drug Safety
    3rd September 2020

    MHRA post-transition period information


    Read more
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    What happens after Brexit for Pharmacovigilance and Regulatory?


    Read more
    Pharmacovigilance (QPPV) provision post-Brexit
    7th February 2020

    Pharmacovigilance (QPPV) provision post-Brexit


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA